company background image
RSLS

ReShape Lifesciences NasdaqCM:RSLS Stock Report

Last Price

US$0.56

Market Cap

US$10.5m

7D

-9.4%

1Y

-87.8%

Updated

01 Jul, 2022

Data

Company Financials +
RSLS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

RSLS Stock Overview

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally.

ReShape Lifesciences Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ReShape Lifesciences
Historical stock prices
Current Share PriceUS$0.56
52 Week HighUS$6.25
52 Week LowUS$0.55
Beta1.53
1 Month Change-40.72%
3 Month Change-50.85%
1 Year Change-87.79%
3 Year Change-93.03%
5 Year Change-100.00%
Change since IPO-100.00%

Recent News & Updates

Mar 31
Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

It's shaping up to be a tough period for ReShape Lifesciences Inc. ( NASDAQ:RSLS ), which a week ago released some...

Shareholder Returns

RSLSUS Medical EquipmentUS Market
7D-9.4%-0.3%-2.5%
1Y-87.8%-24.7%-21.2%

Return vs Industry: RSLS underperformed the US Medical Equipment industry which returned -25.9% over the past year.

Return vs Market: RSLS underperformed the US Market which returned -21.7% over the past year.

Price Volatility

Is RSLS's price volatile compared to industry and market?
RSLS volatility
RSLS Average Weekly Movement12.8%
Medical Equipment Industry Average Movement10.5%
Market Average Movement8.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: RSLS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: RSLS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200247Bart Bandyhttps://www.reshapelifesciences.com

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus.

ReShape Lifesciences Fundamentals Summary

How do ReShape Lifesciences's earnings and revenue compare to its market cap?
RSLS fundamental statistics
Market CapUS$10.47m
Earnings (TTM)-US$65.27m
Revenue (TTM)US$12.82m

0.8x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RSLS income statement (TTM)
RevenueUS$12.82m
Cost of RevenueUS$5.54m
Gross ProfitUS$7.28m
Other ExpensesUS$72.56m
Earnings-US$65.27m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.49
Gross Margin56.81%
Net Profit Margin-509.20%
Debt/Equity Ratio0%

How did RSLS perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is RSLS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RSLS?

Other financial metrics that can be useful for relative valuation.

RSLS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does RSLS's PS Ratio compare to its peers?

RSLS PS Ratio vs Peers
The above table shows the PS ratio for RSLS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average68.2x
GTHP Guided Therapeutics
157.4xn/aUS$13.5m
SINT Sintx Technologies
16.4x77.2%US$10.4m
AVGR Avinger
0.9x21.9%US$8.4m
HYBT Heyu Biological Technology
98xn/aUS$10.1m
RSLS ReShape Lifesciences
0.8x42.8%US$10.5m

Price-To-Sales vs Peers: RSLS is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (68.2x).


Price to Earnings Ratio vs Industry

How does RSLS's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Sales vs Industry: RSLS is good value based on its Price-To-Sales Ratio (0.8x) compared to the US Medical Equipment industry average (3.7x)


Price to Sales Ratio vs Fair Ratio

What is RSLS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RSLS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.8x
Fair PS Ratio5.5x

Price-To-Sales vs Fair Ratio: RSLS is good value based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (5.5x).


Share Price vs Fair Value

What is the Fair Price of RSLS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RSLS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RSLS's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RSLS's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is ReShape Lifesciences forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


55.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RSLS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RSLS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RSLS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RSLS's revenue (42.8% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: RSLS's revenue (42.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RSLS's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has ReShape Lifesciences performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-9.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: RSLS is currently unprofitable.

Growing Profit Margin: RSLS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RSLS is unprofitable, and losses have increased over the past 5 years at a rate of 9.5% per year.

Accelerating Growth: Unable to compare RSLS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RSLS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).


Return on Equity

High ROE: RSLS has a negative Return on Equity (-168.99%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is ReShape Lifesciences's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: RSLS's short term assets ($23.6M) exceed its short term liabilities ($8.2M).

Long Term Liabilities: RSLS's short term assets ($23.6M) exceed its long term liabilities ($494.0K).


Debt to Equity History and Analysis

Debt Level: RSLS is debt free.

Reducing Debt: RSLS had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RSLS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: RSLS has less than a year of cash runway if free cash flow continues to grow at historical rates of 12.3% each year.


Discover healthy companies

Dividend

What is ReShape Lifesciences's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate RSLS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RSLS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RSLS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RSLS's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RSLS has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Bart Bandy (61 yo)

3.17yrs

Tenure

US$377,000

Compensation

Mr. Barton P. Bandy, also known as Bart, has been the President and Chief Executive Officer of ReShape Lifesciences Inc. since April 1, 2019 and has been its Director since May 8, 2019. Mr. Bandy served as...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Bart's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Bart's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: RSLS's management team is considered experienced (2.7 years average tenure).


Board Members

Experienced Board: RSLS's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: RSLS insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 135.8%.


Top Shareholders

Company Information

ReShape Lifesciences Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: ReShape Lifesciences Inc.
  • Ticker: RSLS
  • Exchange: NasdaqCM
  • Founded: 2002
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$10.474m
  • Shares outstanding: 18.69m
  • Website: https://www.reshapelifesciences.com

Number of Employees


Location

  • ReShape Lifesciences Inc.
  • 1001 Calle Amanecer
  • San Clemente
  • California
  • 92673
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/01 00:00
End of Day Share Price2022/07/01 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.